Mouse anti Human CD14, conjugated with FITCCatalog number: 0142
$205.00Add To Cart
Identification of human Monocyte/Macrophage cells expressing the 55 kDa M.W. surface antigen. CD14 is present on 70-93% of Monocyte/Macrophage cells in normal peripheral blood.
Synonyms: CD14 FITC
Product Form: FITC
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
PBMC: Add10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2 to 8°C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add 10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature (20°C). Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope. ALLOPHYCOCYANIN: (APC) conjugates are analyzed in multi-color flow cytometry with instruments equipped with a second laser and proper filters. Laser excitation is at 633 nm with a Helium Neon (HeNe) laser or a 600-640 nm (633 nm) range for a Dye laser. Peak fluorescence emission is at 660 nm.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8°C. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Ship at ambient temperature.
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals unexpectedly frequent reactivity with some myelomonocytic associated antibodies. Woessner S; Florensa L; Besses C; Vila RM; Galles C; Palou L; Sabrafen JS Leuk Res 1992;16(5):505-10 2. Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages. Landmann R; Ludwig C; Obrist R; Obrecht JP J Cell Biochem 1991 Dec;47(4):317-29 3. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Solary E; Casasnovas RO; Campos L; Bene MC; Faure G; Maingon P; Falkenrodt A. Leukemia 1992 May;6(5):393-9 4. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Wood NC; Dickens E; Symons JA; Duff GW Clin Immunol Immunopathol 1992 Mar;62(3):295-300 5. Expression of CD54, CD58, CD14, and HLA-DR on macrophages and macrophage-derived accessory cells and their accessory capacity. Ocklind G; Friedrichs D; Peters JH Immunol Lett 1992 Feb 15;31(3):253-8 6. IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Ruppert J; Friedrichs D; Xu H; Peters JH Immunobiology 1991 Aug;182(5):449-64
Database Name: UniProt
Accession Number: P08571
Safety Datasheet(s) for this product: